Cytomx Therapeutics Stock Buy Hold or Sell Recommendation
| CTMX Stock | USD 1.67 0.06 3.47% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding CytomX Therapeutics is 'Strong Sell'. Macroaxis provides CytomX Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CTMX positions. The advice algorithm takes into account all of CytomX Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting CytomX Therapeutics' buy or sell advice are summarized below:
Real Value 2.04 | Target Price 2.49 | Hype Value 1.72 | Market Value 1.67 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell CytomX Therapeutics given historical horizon and risk tolerance towards CytomX Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for CytomX Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
CytomX |
Execute CytomX Therapeutics Buy or Sell Advice
The CytomX recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on CytomX Therapeutics. Macroaxis does not own or have any residual interests in CytomX Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute CytomX Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
CytomX Therapeutics Trading Alerts and Improvement Suggestions
| CytomX Therapeutics had very high historical volatility over the last 90 days | |
| CytomX Therapeutics may become a speculative penny stock | |
| The company reported the previous year's revenue of 101.21 M. Net Loss for the year was (569 K) with profit before overhead, payroll, taxes, and interest of 53.16 M. | |
| CytomX Therapeutics currently holds about 194.29 M in cash with (56.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| CytomX Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from zacks.com: Viking to Report Q1 Earnings Whats in the Cards |
CytomX Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CytomX analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CytomX analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Hold
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
CytomX Therapeutics Returns Distribution Density
The distribution of CytomX Therapeutics' historical returns is an attempt to chart the uncertainty of CytomX Therapeutics' future price movements. The chart of the probability distribution of CytomX Therapeutics daily returns describes the distribution of returns around its average expected value. We use CytomX Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of CytomX Therapeutics returns is essential to provide solid investment advice for CytomX Therapeutics.
| Mean Return | 0.21 | Value At Risk | -5.8 | Potential Upside | 8.16 | Standard Deviation | 6.16 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of CytomX Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
CytomX Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CytomX Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CytomX Therapeutics backward and forwards among themselves. CytomX Therapeutics' institutional investor refers to the entity that pools money to purchase CytomX Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fmr Inc | 2023-12-31 | 565.3 K | Bridgeway Capital Management, Llc | 2023-12-31 | 434.5 K | Assenagon Asset Management Sa | 2023-12-31 | 404.7 K | Marshall Wace Asset Management Ltd | 0030-12-31 | 363.3 K | Formidable Asset Management Llc | 2023-12-31 | 306.1 K | Tidal Investments Llc. | 2023-12-31 | 306.1 K | State Street Corporation | 2023-12-31 | 267.5 K | Bank Of New York Mellon Corp | 2023-12-31 | 266.8 K | Congress Park Capital Llc | 2023-12-31 | 239.3 K | Bvf Inc | 2023-09-30 | 6.6 M | Tang Capital Management Llc | 2023-09-30 | 6.5 M |
CytomX Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 19.9M | (11.3M) | (11.1M) | 11.6M | 13.4M | 14.1M | |
| Change In Cash | (59.2M) | 3.4M | 13.7M | (11.9M) | (176.5M) | (167.7M) | |
| Free Cash Flow | (144.0M) | 3.0M | (120.6M) | (112.5M) | (56.9M) | (54.0M) | |
| Depreciation | 2.6M | 2.6M | 2.7M | 2.4M | 2.2M | 2.0M | |
| Other Non Cash Items | 1.6M | 2.9M | 3.1M | 3.6M | 27.4M | 28.8M | |
| Capital Expenditures | 3.5M | 2.3M | 1.6M | 1.7M | 840K | 798K | |
| Net Income | (102.2M) | (32.9M) | (83.6M) | (99.3M) | (569K) | (597.5K) | |
| End Period Cash Flow | 189.3M | 192.8M | 206.4M | 194.6M | 17.2M | 16.3M | |
| Investments | 9.7M | 83.2M | (16.4M) | 24.1M | (63.7M) | (60.5M) | |
| Change To Netincome | 16.9M | 20.7M | 14.8M | 13.2M | 15.1M | 14.7M | |
| Change Receivables | 10.0M | 84K | (785K) | 8K | 9.2K | 9.7K |
CytomX Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to CytomX Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that CytomX Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a CytomX stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.06 | |
β | Beta against NYSE Composite | 1.83 | |
σ | Overall volatility | 6.30 | |
Ir | Information ratio | 0.02 |
CytomX Therapeutics Volatility Alert
CytomX Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure CytomX Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact CytomX Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.CytomX Therapeutics Fundamentals Vs Peers
Comparing CytomX Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze CytomX Therapeutics' direct or indirect competition across all of the common fundamentals between CytomX Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as CytomX Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of CytomX Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing CytomX Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare CytomX Therapeutics to competition |
Note: Insider Trading [view details]
CytomX Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as CytomX . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About CytomX Therapeutics Buy or Sell Advice
When is the right time to buy or sell CytomX Therapeutics? Buying financial instruments such as CytomX Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 18.1M | 18.1M | 14.0M | 16.8M | Total Assets | 339.4M | 260.9M | 205.2M | 284.4M |
Use Investing Ideas to Build Portfolios
In addition to having CytomX Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Convertibles Funds Thematic Idea Now
Convertibles Funds
Funds or Etfs that invest in debt that is expected to be converted into a predetermined amount of the company equity at some future date. The Convertibles Funds theme has 22 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Convertibles Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out CytomX Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for CytomX Stock analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is CytomX Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Revenue Per Share 1.371 | Quarterly Revenue Growth 0.322 | Return On Assets (0.02) | Return On Equity (54.75) |
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.